Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance

1.

Rindi G, Mete O, Uccella S et al (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33:115–154. https://doi.org/10.1007/s12022-022-09708-2CrossRefPubMed

2.

Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34:239–277. https://doi.org/10.1210/ER.2012-1013CrossRefPubMedPubMedCentral

3.

Masi G, Barzon L, Iacobone M et al (2008) Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer 15:1115–1126. https://doi.org/10.1677/ERC-08-0066CrossRefPubMed

4.

Sarquis MS, Silveira LG, Pimenta FJ et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 143. https://doi.org/10.1016/j.surg.2007.12.012

5.

Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24:T195–T208. https://doi.org/10.1530/ERC-17-0243CrossRefPubMedPubMedCentral

6.

Frederiksen A, Rossing M, Hermann P et al (2019) Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab 104:3637–3646. https://doi.org/10.1210/JC.2019-00082CrossRefPubMedPubMedCentral

7.

de Kock L, Wu MK, Foulkes WD (2019) Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum Mutat 40:1939–1953. https://doi.org/10.1002/HUMU.23877CrossRefPubMed

8.

Burnichon N, Cascón A, Schiavi F et al (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18:2828–2837. https://doi.org/10.1158/1078-0432.CCR-12-0160CrossRefPubMed

9.

Cascon A, Robledo M (2012) MAX and MYC: a heritable breakup. Cancer Res 72:3119–3124. https://doi.org/10.1158/0008-5472.CAN-11-3891CrossRefPubMed

10.

Brandi ML, Agarwal SK, Perrier ND et al (2021) Multiple endocrine neoplasia type 1: latest insights. Endocr Rev 42:133–170. https://doi.org/10.1210/ENDREV/BNAA031CrossRefPubMed

11.

Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44:81–88. https://doi.org/10.1136/JMG.2006.045906CrossRefPubMed

12.

Stratakis CA (2016) Carney complex: a familial lentiginosis predisposing to a variety of tumors. Rev Endocr Metab Disord 17:367–371. https://doi.org/10.1007/S11154-016-9400-1CrossRefPubMedPubMedCentral

13.

Wells SA, Asa SL, Dralle H et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610. https://doi.org/10.1089/THY.2014.0335CrossRefPubMedPubMedCentral

14.

Moline J, Eng C (2011) Multiple endocrine neoplasia type 2: an overview. Genet Med 13:755–764. https://doi.org/10.1097/GIM.0B013E318216CC6DCrossRefPubMed

15.

Korpershoek E, Favier J, Gaal J et al (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96. https://doi.org/10.1210/JC.2011-1043

16.

Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 72:106–116. https://doi.org/10.1111/HIS.13277CrossRefPubMed

17.

Lubensky IA, Pack S, Ault D et al (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153:223–231. https://doi.org/10.1016/S0002-9440(10)65563-0CrossRefPubMedPubMedCentral

18.

Salama Y, Albanyan S, Szybowska M et al (2019) Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. Clin Genet 96:461–467. https://doi.org/10.1111/CGE.13613CrossRefPubMed

19.

Casar-Borota O, Boldt H, Engström B et al (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 106:1183–1194. https://doi.org/10.1210/CLINEM/DGAA749CrossRefPubMed

20.

Asa SL, Ezzat S (2014) Genomic approaches to problems in pituitary neoplasia. Endocr Pathol 25:209–213. https://doi.org/10.1007/S12022-013-9276-5CrossRefPubMed

21.

Weinstein LS, Yu S, Warner DR, Liu J (2001) Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675–705. https://doi.org/10.1210/EDRV.22.5.0439CrossRefPubMed

22.

Chen J, Jian X, Deng S et al (2018) Identification of recurrent USP48 and BRAF mutations in Cushing’s disease. Nat Commun 9. https://doi.org/10.1038/s41467-018-05275-5

23.

Neou M, Villa C, Armignacco R et al (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37. https://doi.org/10.1016/j.ccell.2019.11.002

24.

Hayashi K, Inoshita N, Kawaguchi K et al (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. Eur J Endocrinol 174:213–226. https://doi.org/10.1530/EJE-15-0689CrossRefPubMed

25.

Asa SL, Mete O, Ezzat S (2021) Genomics and epigenomics of pituitary tumors: What Do Pathologists Need to Know? Endocr Pathol 32:3–16. https://doi.org/10.1007/S12022-021-09663-4CrossRefPubMed

26.

WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023, October, 12]. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https://tumourclassification.iarc.who.int/chapters/53

27.

Chong AS, Nikiforov YE, Condello V et al (2021) Prevalence and spectrum of DICER1 mutations in adult-onset thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab 106. https://doi.org/10.1210/clinem/dgab025

28.

Acquaviva G, Visani M, Repaci A et al (2018) Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology 72:6–31. https://doi.org/10.1111/HIS.13380CrossRefPubMed

29.

González IA, Stewart DR, Schultz KAP et al (2022) DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol 35:4–22. https://doi.org/10.1038/s41379-021-00905-8CrossRefPubMed

30.

Rooper LM, Bynum JP, Miller KP et al (2020) Recurrent DICER1 hotspot mutations in malignant thyroid gland teratomas: molecular characterization and proposal for a separate classification. Am J Surg Pathol 44. https://doi.org/10.1097/PAS.0000000000001430

31.

Calebiro D, Grassi ES, Eszlinger M et al (2016) Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. J Clin Investig 126. https://doi.org/10.1172/JCI84894

32.

Nikiforova MN, Nikitski A V., Panebianco F et al (2019) GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland. Thyroid 29. https://doi.org/10.1089/thy.2018.0791

33.

Krohn K, Führer D, Bayer Y et al (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26:504–524. https://doi.org/10.1210/ER.2004-0005CrossRefPubMed

34.

Lumbroso S, Paris F, Sultan C (2004) Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome–a European Collaborative Study. J Clin Endocrinol Metab 89:2107–2113. https://doi.org/10.1210/JC.2003-031225CrossRefPubMed

35.

Chu YH, Wirth LJ, Farahani AA et al (2020) Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod Pathol 33. https://doi.org/10.1038/s41379-020-0638-5

36.

Dogan S, Wang L, Ptashkin RN et al (2016) Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol 29. https://doi.org/10.1038/modpathol.2016.115

37.

Pekova B, Sykorova V, Dvorakova S et al (2020) RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 30. https://doi.org/10.1089/thy.2019.0802

38.

Oudijk L, Gaal J, de Krijger RR (2019) The role of immunohistochemistry and molecular analysis of succinate dehydrogenase in the diagnosis of endocrine and non-endocrine tumors and related syndromes. Endocr Pathol 30:64–73. https://doi.org/10.1007/S12022-018-9555-2CrossRefPubMed

39.

Asa SL, Mete O (2018) Immunohistochemical biomarkers in pituitary pathology. Endocr Pathol 29:130–136. https://doi.org/10.1007/S12022-018-9521-ZCrossRefPubMed

40.

Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386:2–15. https://doi.org/10.1016/J.MCE.2013.08.002CrossRefPubMedPubMedCentral

41.

Pease M, Ling C, Mack WJ et al (2013) The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature. PLoS One 8. https://doi.org/10.1371/JOURNAL.PONE.0082619

42.

Yang I, Park S, Ryu M et al (1996) Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 134:720–726. https://doi.org/10.1530/EJE.0.1340720CrossRefPubMed

43.

Guo F, Wang G, Wang F et al (2018) Identification of novel genes involved in the pathogenesis of an ACTH-secreting pituitary carcinoma: a case report and literature review. Front Oncol 8. https://doi.org/10.3389/FONC.2018.00510

44.

Ballmann C, Thiel A, Korah HE et al (2018) USP8 mutations in pituitary cushing adenomas-targeted analysis by next-generation sequencing. J Endocr Soc 2:266–278. https://doi.org/10.1210/JS.2017-00364CrossRefPubMedPubMedCentral

45.

Li C, Xie W, Rosenblum JS et al (2020) Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun 11. https://doi.org/10.1038/S41467-020-16052-8

46.

Papathomas TG, Gaal J, Corssmit EPM et al (2013) Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 170:1–12. https://doi.org/10.1530/EJE-13-0623CrossRefPubMed

47.

Tanizaki Y, Jin L, Scheithauer BW et al (2007) P53 gene mutations in pituitary carcinomas. Endocr Pathol 18:217–222. https://doi.org/10.1007/S12022-007-9006-YCrossRefPubMed

48.

No authors listed (1949) Radio-iodine halts one type of cancer: radioactive chemical brings about history-making recovery of patient dying from thyroid tumors. Life Mag 27:54–56

49.

Tallini G, Tuttle RM, Ghossein RA (2017) The history of the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 102:15–22. https://doi.org/10.1210/JC.2016-2976CrossRefPubMed

50.

Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676–690. https://doi.org/10.1016/j.cell.2014.09.050CrossRef

51.

Baloch ZW, Asa SL, Barletta JA et al (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27–63. https://doi.org/10.1007/S12022-022-09707-3CrossRefPubMed

52.

Gasparre G, Porcelli AM, Bonora E et al (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 104:9001–9006. https://doi.org/10.1073/PNAS.0703056104CrossRefPubMedPubMedCentral

53.

Corver WE, Ruano D, Weijers K et al (2012) Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS One 7. https://doi.org/10.1371/JOURNAL.PONE.0038287

54.

Xu B, Fuchs TL, Ahmadi S et al (2022) International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 40:96–103. https://doi.org/10.1200/JCO.21.01329CrossRefPubMed

55.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770–1786CrossRefPubMedPubMedCentral

56.

Landa I, Ibrahimpasic T, Boucai L et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052–1066. https://doi.org/10.1172/JCI85271CrossRefPubMedPubMedCentral

57.

Gandolfi G, Ragazzi M, de Biase D et al (2017) Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. Oncotarget 9:1813–1825. https://doi.org/10.18632/ONCOTARGET.22805CrossRefPubMedPubMedCentral

58.

Chen H, Luthra R, Routbort MJ et al (2018) Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17:1575–1584. https://doi.org/10.1158/1535-7163.MCT-17-0871CrossRefPubMed

59.

Kelly LM, Barila G, Liu P et al (2014) Identification of the transforming STRN-ALK fusion asa potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 111. https://doi.org/10.1073/pnas.1321937111

60.

Chou A, Fraser S, Toon CW et al (2015) A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39. https://doi.org/10.1097/PAS.0000000000000368

61.

Godbert Y, De Figueiredo BH, Bonichon F et al (2015) Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. J Clin Oncol 33:e84–e87. https://doi.org/10.1200/JCO.2013.49.6596CrossRefPubMed

62.

Xu B, Fuchs T, Dogan S et al (2020) Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30:1505–1517. https://doi.org/10.1089/THY.2020.0086CrossRefPubMedPubMedCentral

63.

Xu B, David J, Dogan S et al (2022) Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology 80:322–337. https://doi.org/10.1111/HIS.14550CrossRefPubMed

64.

Ciampi R, Knauf JA, Kerler R et al (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Investig 115. https://doi.org/10.1172/JCI23237

65.

De Biase D, Acquaviva G, Visani M et al (2020) Molecular diagnostic of solid tumor using a next generation sequencing custom-designed multi-gene panel. Diagnostics (Basel) 10. https://doi.org/10.3390/DIAGNOSTICS10040250

66.

de Biase D, Torricelli F, Ragazzi M et al (2018) Not the same thing: metastatic PTCs have a different background than ATCs. Endocr Connect 7:1370–1379. https://doi.org/10.1530/EC-18-0386CrossRefPubMedPubMedCentral

67.

Subbiah V, Kreitman RJ, Wainberg ZA et al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33. https://doi.org/10.1016/j.annonc.2021.12.014

68.

Cameselle-Teijeiro JM, Peteiro-González D, Caneiro-Gómez J et al (2018) Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/?-catenin pathway. Mod Pathol 31:1168–1179. https://doi.org/10.1038/s41379-018-0070-2CrossRefPubMed

69.

Chernock RD, Rivera B, Borrelli N et al (2020) Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Mod Pathol 33. https://doi.org/10.1038/s41379-020-0458-7

70.

Agaimy A, Witkowski L, Stoehr R et al (2020) Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations—is the term “thyroblastoma” more appropriate? Virchows Archiv 477. https://doi.org/10.1007/s00428-020-02853-1

71.

Prasad ML, Vyas M, Horne MJ et al (2016) NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 122. https://doi.org/10.1002/cncr.29887

72.

Kroll TG, Sarraf P, Pecciarini L et al (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357–1360. https://doi.org/10.1126/science.289.5483.1357CrossRefPubMed

73.

Liaw D, Marsh DJ, Li J et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16. https://doi.org/10.1038/ng0597-64

74.

Harach HR, Soubeyran I, Brown A et al (1999) Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 3. https://doi.org/10.1016/S1092-9134(99)80011-2

75.

Ciampi R, Mian C, Fugazzola L et al (2013) Evidence of a low prevalence of ras mutations in a large medullary thyroid cancer series. Thyroid 23. https://doi.org/10.1089/thy.2012.0207

76.

Park H, Shin HC, Yang H et al (2022) Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol 35. https://doi.org/10.1038/s41379-021-00907-6

77.

Evangelisti C, de Biase D, Kurelac I et al (2015) A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer 15. https://doi.org/10.1186/s12885-015-1122-3

78.

Parma J, Duprez L, Van Sande J et al (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649–651. https://doi.org/10.1038/365649a0CrossRefPubMed

79.

Volante M, Lam AK, Papotti M, Tallini G (2021) Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 32:63–76. https://doi.org/10.1007/s12022-021-09665-2CrossRefPubMedPubMedCentral

80.

Ragazzi M, Torricelli F, Donati B et al (2021) Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature. Virchows Arch 478. https://doi.org/10.1007/S00428-020-02891-9

81.

Pozdeyev N, Gay LM, Sokol ES et al (2018) Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 24:3059–3068. https://doi.org/10.1158/1078-0432.CCR-18-0373CrossRefPubMedPubMedCentral

82.

Tallini G, Hsueh A, Liu S et al (1999) Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Investig 79:547–555PubMed

83.

Gopal RK, Kübler K, Calvo SE et al (2018) Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma. Cancer Cell 34. https://doi.org/10.1016/j.ccell.2018.06.013

84.

Nikiforova MN, Lynch RA, Biddinger PW et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–2326. https://doi.org/10.1210/JC.2002-021907CrossRefPubMed

85.

Abi-Raad R, Prasad ML, Adeniran AJ, Cai G (2022) Copy number variations identified in thyroid FNA specimens are associated with Hürthle cell cytomorphology. Cancer Cytopathol 130. https://doi.org/10.1002/cncy.22569

86.

Xin Y, Zhao T, Wei B et al (2020) Intrapericardial parathyroid carcinoma: a case report. Endocrine 69:456–460. https://doi.org/10.1007/S12020-020-02283-8CrossRefPubMed

87.

Perren A, Mete O, Williams MD, Johnson SJ, Juhlin CC (2022) Parathyroid adenoma. In: WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours, 5th ed. IARC, Lyon. Available from: https://tumourclassification.iarc.who.int/chapters/53

88.

DeLellis RA (2011) Parathyroid tumors and related disorders. Mod Pathol 24(Suppl 2):S78-93CrossRefPubMed

89.

Erickson LA, Mete O (2018) Immunohistochemistry in diagnostic parathyroid pathology. Endocr Pathol 29:113–129. https://doi.org/10.1007/S12022-018-9527-6CrossRefPubMed

90.

Gill AJ, Lim G, Cheung VKY et al (2019) Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) parathyroid tumors demonstrate distinctive morphologic features. Am J Surg Pathol 43:35–46. https://doi.org/10.1097/PAS.0000000000001017CrossRefPubMed

91.

Thakker RV (2016) Genetics of parathyroid tumours. J Intern Med 280:574–583. https://doi.org/10.1111/JOIM.12523CrossRefPubMed

92.

Seabrook AJ, Harris JE, Velosa SB et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106:1163–1182. https://doi.org/10.1210/CLINEM/DGAA957CrossRefPubMed

93.

Turchini J, Gill AJ (2020) Hereditary parathyroid disease: sometimes pathologists do not know what they are missing. Endocr Pathol 31:218–230. https://doi.org/10.1007/S12022-020-09631-4CrossRefPubMed

94.

Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671. https://doi.org/10.1210/JCEM.86.12.8070CrossRefPubMed

95.

Rege J, Nanba K, Blinder AR et al (2020) Identification of somatic mutations in CLCN2 in aldosterone-producing adenomas. J Endocr Soc 4:1–9. https://doi.org/10.1210/JENDSO/BVAA123CrossRef

96.

Åkerström T, Maharjan R, Sven Willenberg H et al (2016) Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 6. https://doi.org/10.1038/SREP19546

97.

Di Dalmazi G, Kisker C, Calebiro D et al (2014) Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing’s syndrome: a European multicentric study. J Clin Endocrinol Metab 99:E2093–E2100. https://doi.org/10.1210/JC.2014-2152CrossRefPubMed

98.

Beuschlein F, Fassnacht M, Assié G et al (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med 370:1019–1028. https://doi.org/10.1056/NEJMOA1310359CrossRefPubMedPubMedCentral

99.

Fassnacht M, Dekkers OM, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179:G1–G46. https://doi.org/10.1530/EJE-18-0608CrossRefPubMed

100.

Kamilaris CDC, Hannah-Shmouni F, Stratakis CA (2020) Adrenocortical tumorigenesis: lessons from genetics. Best Pract Res Clin Endocrinol Metab 34:101428CrossRefPubMedPubMedCentral

101.

Raymond VM, Everett JN, Furtado LV et al (2013) Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 31:3012–3018. https://doi.org/10.1200/JCO.2012.48.0988CrossRefPubMedPubMedCentral

102.

Virgone C, Andreetta M, Avanzini S et al (2020) Pheochromocytomas and paragangliomas in children: data from the Italian Cooperative Study (TREP). Pediatr Blood Cancer 67. https://doi.org/10.1002/PBC.28332

103.

Henry I, Jeanpierre M, Couillin P et al (1989) Molecular definition of the 11p15.5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma. Hum Genet 81:273–277. https://doi.org/10.1007/BF00279003CrossRefPubMed

104.

Schmitt A, Saremaslani P, Schmid S, Rousson V, Montani M, Schmid DM, Heitz PU, Komminoth P, Perren A (2006) IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49:298–307CrossRefPubMed

105.

Brewer K, Costa-Guda J, Arnold A (2019) Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr Relat Cancer 26:R53–R72. https://doi.org/10.1530/ERC-18-0304CrossRefPubMed

106.

Hong YA, Park KC, Kim BK et al (2021) Analyzing genetic differences between sporadic primary and secondary/tertiary hyperparathyroidism by targeted next-generation panel sequencing. Endocr Pathol 32:501–512. https://doi.org/10.1007/S12022-021-09686-XCrossRefPubMed

107.

Costa-Guda J, Marinoni I, Molatore S et al (2011) Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 96. https://doi.org/10.1210/JC.2010-1338

108.

Sulaiman L, Haglund F, Hashemi J et al (2012) Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors. PLoS One 7. https://doi.org/10.1371/JOURNAL.PONE.0046325

109.

Korpi-Hyövälti E, Cranston T, Ryhänen E et al (2014) CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. J Clin Endocrinol Metab 99:3044–3048. https://doi.org/10.1210/jc.2014-1481CrossRefPubMedPubMedCentral

110.

Bricaire L, Odou MF, Cardot-Bauters C et al (2013) Frequent large germline HRPT2 deletions in a french national cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98. https://doi.org/10.1210/jc.2012-2789

111.

Haven CJ, Van Puijenbroek M, Tan MH et al (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 67. https://doi.org/10.1111/j.1365-2265.2007.02894.x

112.

Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547–554. https://doi.org/10.1530/EJE-06-0720CrossRefPubMed

113.

Hunt JL, Carty SE, Yim JH et al (2005) Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 29. https://doi.org/10.1097/01.pas.0000166368.68459.99

114.

Gill AJ, Clarkson A, Gimm O et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–1149. https://doi.org/10.1097/01.PAS.0000209827.39477.4FCrossRefPubMed

115.

Hu Y, Zhang X, Wang O et al (2020) The genomic profile of parathyroid carcinoma based on whole-genome sequencing. Int J Cancer 147:2446–2457. https://doi.org/10.1002/IJC.33166CrossRefPubMed

116.

Cryns VL, Rubio MP, Thor AD et al (1994) p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78. https://doi.org/10.1210/jcem.78.6.8200932

117.

Pandya C, Uzilov A V., Bellizzi J et al (2017) Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2. https://doi.org/10.1172/jci.insight.92061

118.

Kang H, Pettinga D, Schubert AD et al (2019) Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist 24. https://doi.org/10.1634/theoncologist.2018-0334

119.

Haven CJ, van Puijenbroek M, Karperien M et al (2004) Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 202:86–94. https://doi.org/10.1002/PATH.1489CrossRefPubMed

120.

Condello V, Cetani F, Denaro M et al (2021) Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocr Relat Cancer 28. https://doi.org/10.1530/ERC-20-0337

121.

Starker LF, Svedlund J, Udelsman R et al (2011) The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer 50:735–745. https://doi.org/10.1002/GCC.20895CrossRefPubMedPubMedCentral

122.

Hodgson A, Pakbaz S, Mete O (2019) A diagnostic approach to adrenocortical tumors. Surg Pathol Clin 12:967–995. https://doi.org/10.1016/j.path.2019.08.005CrossRefPubMed

123.

Carney JA, Hruska LS, Beauchamp GD, Gordon H (1986) Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 61. https://doi.org/10.1016/S0025-6196(12)61843-6

124.

Assié G, Libé R, Espiard S et al (2013) ARMC5 mutations in macronodular adrenal hyperplasia with cushing’s syndrome. N Engl J Med 369. https://doi.org/10.1056/nejmoa1304603

125.

Matyakhina L, Freedman RJ, Bourdeau I et al (2005) Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 90. https://doi.org/10.1210/jc.2004-2377

126.

Juhlin CC, Bertherat J, Giordano TJ et al (2021) What did we learn from the molecular biology of adrenal cortical neoplasia? From histopathology to translational genomics. Endocr Pathol 32:102–133. https://doi.org/10.1007/s12022-021-09667-0CrossRefPubMed

127.

Wannachalee T, Zhao L, Nanba K et al (2019) Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling. J Clin Endocrinol Metab 104:5867–5876. https://doi.org/10.1210/JC.2019-01182CrossRefPubMedPubMedCentral

128.

Azizan EAB, Lam BYH, Newhouse SJ et al (2012) Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 97. https://doi.org/10.1210/JC.2011-2965

129.

Faillot S, Foulonneau T, Néou M et al (2021) Genomic classification of benign adrenocortical lesions. Endocr Relat Cancer 28. https://doi.org/10.1530/ERC-20-0128

130.

Mulatero P, Schiavi F, Williams TA et al (2016) ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J Hum Hypertens 30:374–378. https://doi.org/10.1038/JHH.2015.98CrossRefPubMed

131.

de Krijger RE, Bertherat J (2016) 5th International ACC Symposium: Classification of adrenocortical cancers from pathology to integrated genomics: real advances or lost in translation? Horm Cancer 7:3–8. https://doi.org/10.1007/s12672-015-0242-1CrossRefPubMed

132.

Assié G, Letouzé E, Fassnacht M et al (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46. https://doi.org/10.1038/ng.2953

133.

Zheng S, Cherniack AD, Dewal N et al (2016) Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29:723–736. https://doi.org/10.1016/J.CCELL.2016.04.002CrossRefPubMedPubMedCentral

134.

Assié G, Jouinot A, Fassnacht M et al (2019) Value of molecular classification for prognostic assessment of adrenocortical carcinoma. JAMA Oncol 5:1440–1447. https://doi.org/10.1001/JAMAONCOL.2019.1558CrossRefPubMed

135.

Juhlin CC, Villablanca A, Sandelin K et al (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14. https://doi.org/10.1677/ERC-07-0021.

136.

Espiard S, Drougat L, Libé R et al (2015) ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences. J Clin Endocrinol Metab 100. https://doi.org/10.1210/jc.2014-4204

137.

Espiard S, Vantyghem MC, Assié G et al (2020) Frequency and incidence of carney complex manifestations: a prospective multicenter study with a three-year follow-up. J Clin Endocrinol Metab 105. https://doi.org/10.1210/clinem/dgaa002

138.

Choi M, Scholl UI, Yue P et al (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331:768–772. https://doi.org/10.1126/SCIENCE.1198785CrossRefPubMedPubMedCentral

139.

Beuschlein F, Boulkroun S, Osswald A et al (2013) Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 45:440–444. https://doi.org/10.1038/NG.2550CrossRefPubMed

140.

Scholl UI, Stölting G, Nelson-Williams C et al (2015) Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 4:e06315. https://doi.org/10.7554/ELIFE.06315CrossRefPubMedPubMedCentral

141.

Scholl UI, Stölting G, Schewe J et al (2018) CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 50:349–354. https://doi.org/10.1038/S41588-018-0048-5CrossRefPubMedPubMedCentral

142.

Lenzini L, Rossitto G, Maiolino G et al (2015) A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab 100:E1089–E1095. https://doi.org/10.1210/JC.2015-2149CrossRefPubMed

143.

Juhlin CC, Goh G, Healy JM et al (2015) Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 100:E493–E502. https://doi.org/10.1210/JC.2014-3282CrossRefPubMed

144.

Giordano TJ, Kuick R, Else T et al (2009) Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668–676. https://doi.org/10.1158/1078-0432.CCR-08-1067CrossRefPubMedPubMedCentral

145.

Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181–193. https://doi.org/10.1016/J.CCELL.2017.01.001CrossRefPubMedPubMedCentral

146.

Papathomas TG, Suurd DPD, Pacak K et al (2021) What have we learned from molecular biology of paragangliomas and pheochromocytomas? Endocr Pathol 32:134–153. https://doi.org/10.1007/S12022-020-09658-7CrossRefPubMed

147.

Turchini J, Cheung VKY, Tischler AS et al (2018) Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 72:97–105. https://doi.org/10.1111/HIS.13402CrossRefPubMed

148.

Ebbehoj A, Stochholm K, Jacobsen SF et al (2021) Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study. J Clin Endocrinol Metab 106:E2251–E2261. https://doi.org/10.1210/CLINEM/DGAA965CrossRefPubMed

149.

Bholah R, Bunchman TE (2017) Review of pediatric pheochromocytoma and paraganglioma. Front Pediatr 5. https://doi.org/10.3389/FPED.2017.00155

150.

de Tersant M, Généré L, Freyçon C et al (2020) Pheochromocytoma and paraganglioma in children and adolescents: experience of the French Society of Pediatric Oncology (SFCE). J Endocr Soc 4. https://doi.org/10.1210/JENDSO/BVAA039

151.

Erickson D, Kudva YC, Ebersold MJ et al (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86:5210–5216. https://doi.org/10.1210/JCEM.86.11.8034CrossRefPubMed

152.

Dannenberg H, van Nederveen FH, Abbou M et al (2005) Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol 23:1894–1901. https://doi.org/10.1200/JCO.2005.07.198CrossRefPubMed

153.

Smith JD, Harvey RN, Darr OA et al (2017) Head and neck paragangliomas: a two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol 2:380–389. https://doi.org/10.1002/LIO2.122CrossRefPubMedPubMedCentral

154.

Bernardo-Castiñeira C, Valdés N, Sierra MI et al (2018) SDHC promoter methylation, a novel pathogenic mechanism in parasympathetic paragangliomas. J Clin Endocrinol Metab 103:295–305. https://doi.org/10.1210/JC.2017-01702CrossRefPubMed

155.

Settas N, Faucz FR, Stratakis CA (2018) Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome. Mol Cell Endocrinol 469:107–111. https://doi.org/10.1016/J.MCE.2017.07.018CrossRefPubMed

156.

Burnichon N, Buffet A, Parfait B et al (2012) Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 21:5397–5405. https://doi.org/10.1093/HMG/DDS374CrossRefPubMed

157.

Welander J, Larsson C, Bäckdahl M et al (2012) Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 21:5406–5416. https://doi.org/10.1093/HMG/DDS402CrossRefPubMed

158.

Dahia PLM, Ross KN, Wright ME et al (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:0072–0080. https://doi.org/10.1371/JOURNAL.PGEN.0010008CrossRef

159.

Boedeker CC, Hensen EF, Neumann HPH et al (2014) Genetics of hereditary head and neck paragangliomas. Head Neck 36:907–916. https://doi.org/10.1002/HED.23436CrossRefPubMed

EASD 2024

Springer Medicine

Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance

Abstract

EASD 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Correction to: The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: An updated review

Molecular pathology as basis for timely cancer diagnosis and therapy

Molecular features for timely cancer diagnosis and treatment – tumors of the ovary, fallopian tube and endometrium

Correction to: Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance

Molecular diagnostics of hepatobiliary and pancreatic neoplasias

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers